Gastroenterology
Volume 124, Issue 6 , Pages 1662-1671 , June 2003

Postinfectious irritable bowel syndrome1

  • Robin C. Spiller

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Professor Robin C. Spiller, Division of Gastroenterology, University Hospital, Nottingham, NG7 2UH United Kingdom fax: (44) 0115 9422232
    • Division of Gastroenterology, University Hospital, Nottingham, United Kingdom

Received 17 December 2002 ,Accepted 9 January 2003.

References 

  1. Longstreth GF, Hawkey CJ, Ham J, Jones RH, Mayer EA, Naesdal J, et al. Demographic and clinical characteristics of patients with irritable bowel syndrome (IBS) from three practice settings. Gastroenterology. 2000;118:A146
  2. Boulton-Jones R, Spiller RC. Significance of anxiety in IBS outpatients (relation to bowel symptoms and final diagnosis). Gut. 2002;52(Suppl 1):A86
  3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):II43–II47
  4. Dunlop SP, Jenkins D, Spiller RC. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS. Gastroenterology. 2002;122(Suppl 1):A60
  5. Stewart GT. Post-dysenteric colitis. Br Med J. 1950;i:405–409
  6. Chaudhary NA, Truelove SC. The irritable colon syndrome. QJM. 1962;123:307–322
  7. McKendrick MW, Read NW. Irritable bowel syndrome—post Salmonella infection. J Infect. 1994;29:1–3
  8. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, et al.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150–153
  9. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al.  The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–406
  10. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome (postal survey of patients). BMJ. 1997;314:779–782 [see comments]
  11. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis. 2001;184:606–609
  12. Parry SD, Barton JR, Welfare MR. Does infectious diarrhoea (ID) predispose people to functional gastro-intestinal disorders (FGIDs)? A prospective community case-control study. Gut. 2002;50:1
  13. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis (cohort study). BMJ. 1999;318:565–566
  14. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS, et al.  Study of infectious intestinal disease in England (rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive). Br Med J. 1999;318:1046–1050
  15. Huerta C, Garcia Rodriguez LA, Wallander MA, Johansson S. Risk of irritable bowel syndrome among asthma patients. Pharmacoepidemiol Drug Saf. 2002;11:31–35
  16. Georges-Courbot MC, Cassel-Beraud AM, Gouandjika I, Monges J, Georges AJ. A cohort study of enteric campylobacter infection in children from birth to two years in Bangui (Central African Republic). Trans R Soc Trop Med Hyg. 1990;84:122–125
  17. Kapoor KK, Nigam P, Rastogi CK, Kumar A, Gupta AK. Clinical profile of irritable bowel syndrome. Indian J Gastroenterol. 1985;4:15–16
  18. Wei X, Chen M, Wang J. The epidemiology of irritable bowel syndrome and functional constipation of Guangzhou residents. Zhonghua Nei Ke Za Zhi. 2001;40:517–520
  19. Pan G, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing (stratified randomized study by cluster sampling). Chin Med J (Engl). 2000;113:35–39
  20. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome (a six year follow up study). Gut. 2002;51:410–413
  21. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, et al.  Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988;95:701–708
  22. Anand AC, Reddy PS, Saiprasad GS, Kher SK. Does non-dysenteric intestinal amoebiasis exist?. Lancet. 1997;349:89–92
  23. Chan J, Gonsalkorale W, Perrey M. IL-10 and TGF-beta phenotype in irritable bowel syndrome (evidence to support an inflammatory component (abstr)). Gastroenterology. 2000;118:A184
  24. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101–1108
  25. Blaser MJ, Berkowitz ID, LaForce FM, Cravens J, Reller LB, Wang WL. Campylobacter enteritis (clinical and epidemiologic features). Ann Intern Med. 1979;91:179–185
  26. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al.  Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811
  27. Playford RJ, Domin J, Beacham J, Parmar KB, Tatemoto K, Bloom SR, et al.  Preliminary report (role of peptide YY in defence against diarrhoea). Lancet. 1990;335:1555–1557
  28. Bjarnason I, Maxton D, Reynolds AP, Catt S, Peters TJ, Menzies IS. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol. 1994;29:630–639
  29. Chavez AM, Menconi MJ, Hodin RA, Fink MP. Cytokine-induced intestinal epithelial hyperpermeability (role of nitric oxide). Crit Care Med. 1999;27:2246–2251
  30. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, et al.  Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol. 2002;97:2000–2004
  31. Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett P, Collins SM. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology. 2001;120:1729–1736
  32. Linden DR, Sharkey KA, Mawe GM. Inflammation is associated with an increased availability of serotonin from enterochromaffin cells in the guinea pig distal colon. FASEB J. 2002;16:A890
  33. Wheatcroft J, Wakelin D, Jenkins D, Spiller RC. Increased entero-endocrine cell numbers in the Trichinella spiralis infected mouse model of post-infectious bowel dysfunction. Gastroenterology. 2002;122(Suppl 1):A162
  34. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–468
  35. Camilleri MJ, McKinzie S, Burton D, Thomforde GM, Zinsmeister AR, Bouras EP. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology. 2000;118:A845
  36. Kozlowski CM, Green A, Grundy D, Boissonade FM, Bountra C. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut. 2000;46:474–480
  37. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998;12:249–271
  38. Cann PA, Read NW, Brown C. Irritable bowel syndrome (relationship of disorders in the transit of a single solid meal to symptom patterns). Gut. 1983;24:405–411
  39. Szajewska H, Kantecki M, Albrecht P, Antoniewicz J. Carbohydrate intolerance after acute gastroenteritis—a disappearing problem in Polish children. Acta Paediatr. 1997;86:347–350
  40. Parry SD, Barton JR, Welfare MR. Is lactose intolerance implicated in the development of post-infectious bowel symptoms in previously asymptomatic people?. Gut. 2002;50:301
  41. Lisker R, Aguilar L, Zavala C. Intestinal lactase deficiency and milk drinking capacity in the adult. Am J Clin Nutr. 1978;31:1499–1503
  42. Perk G, Ackerman Z, Cohen P, Eliakim R. Lymphocytic colitis (a clue to an infectious trigger). Scand J Gastroenterol. 1999;34:110–112
  43. Miehlke S, Heymer P, Bethke B, Bastlein E, Meier E, Bartram HP, et al.  Budesonide treatment for collagenous colitis (a randomized, double-blind, placebo-controlled, multicenter trial). Gastroenterology. 2002;123:978–984
  44. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506
  45. Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME, et al.  Association of adult coeliac disease with irritable bowel syndrome (a case-control study in patients fulfilling ROME II criteria referred to secondary care). Lancet. 2001;358:1504–1508
  46. Lai Ping SA, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis. 1997;8:22–32
  47. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000;47(Suppl 2):II1–II19
  48. Parker TJ, Naylor SJ, Riordan AM, Hunter JO. Management of patients with food intolerance in irritable bowel syndrome (the development and use of an exclusion diet). J Hum Nutr Diet. 1995;8:159–166
  49. Barrow L, Steed KP, Spiller RC, Maskell NA, Brown JK, Watts PJ, et al.  Quantitative, noninvasive assessment of antidiarrhoeal actions of codeine using an experimental model of diarrhea in man. Dig Dis Sci. 1993;38:996–1003
  50. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980;79:1272–1275
  51. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 1984;29:239–247
  52. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;22:81–84
  53. Myren J, Lovland B, Larssen S-E, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 1984;19:835–843
  54. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256
  55. Riberdy-Poitras M, Verrier P, Plourde V, Boivin M, Poitras P. Amitriptylin for the treatment of IBS. Gastroenterology. 2000;118:A617
  56. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, et al.  GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990;35:477–480
  57. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al.  Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–1159
  58. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:175–180
  59. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome (a pilot study). Gut. 1998;42:42–46
  60. Williams AJK, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption—a review of clinical presentation, diagnosis, and response to treatment. Gut. 1991;32:1004–1006
  61. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond. 1997;31:53–56
  62. Tazume S, Ozawa A, Yamamoto T, Takahashi Y, Takeshi K, Saidi SM, et al.  Ecological study on the intestinal bacterial flora of patients with diarrhea. Clin Infect Dis. 1993;16:S77–S82
  63. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187–1189
  64. Isolauri E, Kaila M, Mykkanen H, Ling WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci. 1994;39:2595–2600
  65. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children (a meta-analysis). Dig Dis Sci. 2002;47:2625–2634
  66. O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis. 2000;32:294–301
  67. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231–1238
  68. Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology. 1998;114:29–36
  69. Riordan SM, McIver CJ, Duncombe VM, Thomas MC, Nagree A, Bolin TD. Small intestinal bacterial overgrowth and the irritable bowel syndrome. Am J Gastroenterol. 2001;96:2506–2508
  70. McKendrick MW. Post Salmonella irritable bowel syndrome-5-year review. J Infect. 1996;33:170–171
  71. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome (a 5-year prospective study). Lancet. 1987;1:963–965
  72. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut. 1998;43:256–261

PII: S0016-5085(03)00324-X

doi: 10.1016/S0016-5085(03)00324-X

Gastroenterology
Volume 124, Issue 6 , Pages 1662-1671 , June 2003

Article Tools

* Image Usage & Resolution